Molecule
Apomorphine is a dopaminergic agonist indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease. It is available as injection for subcutaneous use. MedsAcross supplies Apomorphine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ONAPGO is a dopaminergic agonist indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Source: US FDA prescribing information
ONAPGO is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Source: US FDA prescribing information
For subcutaneous use by infusion only. Maximum recommended total daily dosage of ONAPGO, including the continuous dosage and any extra dose(s), is 98 mg generally administered over the waking day (e.g., 16 hours). The recommended initial continuous dosage is 1 mg/hr with a maximum of 6 mg/hr for up to 16 hours per day. For patients who require an extra dose, initiate the first extra dose at 0.5 mg. Subsequent extra doses may be titrated in increments of 0.1 mg to 1 mg, based on clinical response and tolerability. The maximum extra dose is 2 mg. Administer with at least 3 hours between extra doses and a maximum of 3 extra doses per day. Treatment with trimethobenzamide is recommended, starting 3 days prior to the first dose of ONAPGO, and should only be continued as long as necessary to control nausea and vomiting, and generally no longer than two months.
Source: US FDA prescribing information
ONAPGO is contraindicated in patients: Using concomitant 5HT 3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron. There have been reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. With hypersensitivity/allergic reaction to apomorphine or any of the excipients of ONAPGO, including sulfite (i.e., sodium metabisulfite). Angioedema or anaphylaxis may occur. Concomitant use of ONAPGO with 5HT 3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron.
Source: US FDA prescribing information
Subcutaneous use only, thrombus formation and pulmonary embolism have followed intravenous administration of ONAPGO. May cause nausea and vomiting. Falling asleep during activities of daily living and daytime somnolence may occur. May cause hypotension/orthostatic hypotension and syncope may occur. May cause or increase the risk of falls. May cause infusion site reactions and infections. Monitor and change infusion site every day. May cause hallucinations and psychotic-like behavior. May cause dyskinesia or exacerbate pre-existing dyskinesia. May cause hemolytic anemia. May cause impulse control/compulsive and impulsive behaviors. Consider dose reductions or stopping ONAPGO. May cause cardiac events. May prolong QTc and cause torsades de pointes or sudden death.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Adverse Reactions After Intravenous Administration Nausea and Vomiting Falling Asleep During Activities of Daily Living and Somnolence Syncope/Hypotension/Orthostatic Hypotension Falls Infusion Site Reactions and Infections Hallucinations/Psychotic-Like Behavior Dyskinesia Hemolytic Anemia Impulse Control/Compulsive Behaviors Cardiac Events QTc Prolongation and Potential for Proarrhythmic Effects Hypersensitivity Fibrotic Complications Priapism Most common adverse reactions (incidence ≥10% on ONAPGO and at least twice the rate of placebo) were infusion site nodule, nausea, somnolence, infusion site erythema, dyskinesia, headache, and insomnia.
Source: US FDA prescribing information
Concomitant use of antihypertensive medications and vasodilators: increased risk for hypotension, falls, and injuries. Dopamine antagonists, such as neuroleptics or metoclopramide, may diminish the effectiveness of ONAPGO. 7.1 5HT 3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of ONAPGO with 5HT 3 antagonists, including antiemetics (e.g., ondansetron, granisetron, palonosetron) and alosetron, is contraindicated.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Apomorphine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Apokyn 30 mg/3 mL injectionSubcutaneous | MDD US Operations | US FDA | Available on request |
| apomorphine hydrocloride 30 mg/3 mL injectionSubcutaneous | TruPharma | US FDA | Available on request |
| Onapgo 98 mg/20 mL injectionSubcutaneous | MDD US Operations | US FDA | Available on request |
3 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Apomorphine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Apomorphine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Apomorphine, including Apokyn, apomorphine hydrocloride, Onapgo.
Yes. The US FDA first approved Apomorphine on 20 April 2004, according to Drugs@FDA.
No listed presentation of Apomorphine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Apomorphine is classified under ATC code G04BE07 (Apomorphine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.